Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Until recently, the standard of care for hepatitis C virus (HCV) infection has been pegylated interferon and ribavirin for 48 weeks for genotype 1 and 24 weeks for genotype 3 infection, with overall sustained virological response (SVR), which equates to cure, of 50% and 80%, respectively. With the recent licensing of the protease inhibitors telaprevir and boceprevir, first generation direct acting antivirals (DAAs), we are at the dawn of a new era of HCV therapy. The ILLUMINATE study explores response-guided therapy in HCV treatment naïve individuals using telaprevir in combination with pegylated interferon and ribavirin.
ILLUMINATE is a phase 3 non-inferiority study exploring shorter course therapy for HCV infection …
Competing interests None.